Tchempix coated tablets 1 mg. №28

$193.00

For the amusement of the Tyutunovo deposits at the overgrowth. For the sake of stasis, it becomes stagnant with nicotine deposits. Vareniklіn.

Storage
0.5 mg tablets:
active substance: varenicline tartrate;
1 film-coated tablet contains 0.85 mg of varenicline tartrate, which is equivalent to 0.5 mg of varenicline;
excipients: microcrystalline cellulose, calcium phosphate dibasic anhydrous, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate;
shell Opadray® white (YS-1-18202-A): hypromellose, titanium dioxide (E 171), polyethylene glycol; Opadray® transparent (YS-2-19114-A): hypromellose, triacetin;

1 mg tablets:
active substance: varenicline tartrate;
1 film-coated tablet contains 1.71 mg of varenicline tartrate, which is equivalent to 1 mg of varenicline;
excipients: microcrystalline cellulose, calcium phosphate dibasic anhydrous, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate;
shell: Opadray® blue (03B90547): hypromellose, polyethylene glycol, titanium dioxide (E 171), FD & C blue № 2 / indigo carmine aluminum varnish (E 132); Opadray® transparent (YS-2-19114-A): hypromellose, triacetin.

Dosage form
Film-coated tablets.
Basic physical and chemical properties:
0.5 mg tablets: film-coated tablets, white to off-white, biconvex, capsule-shaped, debossed with “Pfizer” on one side and “CHX 0.5” on the other;
1 mg tablets: film-coated tablets, light blue, biconvex, capsule-shaped, debossed with “Pfizer” on one side and “CHX 1.0” on the other.
Pharmacological properties
Mechanism of action. Varenicline binds with high affinity and selectivity to α4β2-nicotinic acetylcholine receptors in neurons, for which it acts as a partial agonist: it has both agonistic activity (with lower intrinsic activity than nicotine) and antagonistic activity.
In vitro electrophysiological and in vivo neurochemical studies have shown that varenicline binds to α4β2-nicotinic acetylcholine receptors in neurons and stimulates receptor-mediated activity, but at a much lower level than nicotine. Nicotine binds competitively to the same region of α4β2-nicotinic acetylcholine receptors in human neurons with which varenicline is more closely related. Thus, varenicline can effectively block the ability of nicotine to fully activate α4β2 receptors and the mesolimbic dopamine system – the neuronal mechanism underlying the mechanisms of nicotine dependence (smoking pleasure). Varenicline is a highly selective substance that binds more strongly to the α4β2 receptor subtype (Ki = 0.15 nmol) than to other common nicotinic receptors (α3β4 – Ki = 84 nmol, α7 – Ki = 620 nmol, α1βγδ – Ki = 3 400 nmol) or non-nicotine receptors and transporters (Ki> 1 μmol, except for 5-HT3 receptors: Ki = 350 nmol).
Pharmacodynamic action. The efficacy of Champix as a treatment for nicotine dependence is due to the partial agonistic effect of varenicline on α4β2-nicotinic receptors, binding to which reduces the symptoms of smoking cessation and withdrawal symptoms (agonistic effect) and at the same time prevents α2 receptor binding. which ultimately leads to a decrease in smoking pleasure (antagonistic effect).
Clinical efficacy and safety. The efficacy of Champix in eliminating nicotine dependence was established in three clinical trials involving chronic smokers (≥ 10 cigarettes per day). 2619 patients received Champix 1 mg twice daily (dose titrated during the first week), 669 patients received bupropion 150 mg twice daily (dose was also titrated), and 684 patients received placebo.
Indication
To get rid of tobacco addiction in adults.
Contraindication
Hypersensitivity to the active substance or to any of the other excipients.

Category:

Description

Storage
0.5 mg tablets:
active substance: varenicline tartrate;
1 film-coated tablet contains 0.85 mg of varenicline tartrate, which is equivalent to 0.5 mg of varenicline;
excipients: microcrystalline cellulose, calcium phosphate dibasic anhydrous, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate;
shell Opadray® white (YS-1-18202-A): hypromellose, titanium dioxide (E 171), polyethylene glycol; Opadray® transparent (YS-2-19114-A): hypromellose, triacetin;

1 mg tablets:
active substance: varenicline tartrate;
1 film-coated tablet contains 1.71 mg of varenicline tartrate, which is equivalent to 1 mg of varenicline;
excipients: microcrystalline cellulose, calcium phosphate dibasic anhydrous, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate;
shell: Opadray® blue (03B90547): hypromellose, polyethylene glycol, titanium dioxide (E 171), FD & C blue № 2 / indigo carmine aluminum varnish (E 132); Opadray® transparent (YS-2-19114-A): hypromellose, triacetin.

Dosage form
Film-coated tablets.
Basic physical and chemical properties:
0.5 mg tablets: film-coated tablets, white to off-white, biconvex, capsule-shaped, debossed with “Pfizer” on one side and “CHX 0.5” on the other;
1 mg tablets: film-coated tablets, light blue, biconvex, capsule-shaped, debossed with “Pfizer” on one side and “CHX 1.0” on the other.
Pharmacological properties
Mechanism of action. Varenicline binds with high affinity and selectivity to α4β2-nicotinic acetylcholine receptors in neurons, for which it acts as a partial agonist: it has both agonistic activity (with lower intrinsic activity than nicotine) and antagonistic activity.
In vitro electrophysiological and in vivo neurochemical studies have shown that varenicline binds to α4β2-nicotinic acetylcholine receptors in neurons and stimulates receptor-mediated activity, but at a much lower level than nicotine. Nicotine binds competitively to the same region of α4β2-nicotinic acetylcholine receptors in human neurons with which varenicline is more closely related. Thus, varenicline can effectively block the ability of nicotine to fully activate α4β2 receptors and the mesolimbic dopamine system – the neuronal mechanism underlying the mechanisms of nicotine dependence (smoking pleasure). Varenicline is a highly selective substance that binds more strongly to the α4β2 receptor subtype (Ki = 0.15 nmol) than to other common nicotinic receptors (α3β4 – Ki = 84 nmol, α7 – Ki = 620 nmol, α1βγδ – Ki = 3 400 nmol) or non-nicotine receptors and transporters (Ki> 1 μmol, except for 5-HT3 receptors: Ki = 350 nmol).
Pharmacodynamic action. The efficacy of Champix as a treatment for nicotine dependence is due to the partial agonistic effect of varenicline on α4β2-nicotinic receptors, binding to which reduces the symptoms of smoking cessation and withdrawal symptoms (agonistic effect) and at the same time prevents α2 receptor binding. which ultimately leads to a decrease in smoking pleasure (antagonistic effect).
Clinical efficacy and safety. The efficacy of Champix in eliminating nicotine dependence was established in three clinical trials involving chronic smokers (≥ 10 cigarettes per day). 2619 patients received Champix 1 mg twice daily (dose titrated during the first week), 669 patients received bupropion 150 mg twice daily (dose was also titrated), and 684 patients received placebo.
Indication
To get rid of tobacco addiction in adults.
Contraindication
Hypersensitivity to the active substance or to any of the other excipients.

Method of application and dosage
Champix should be administered orally. Swallow the tablets whole with water. Champix can be taken with or without food.
The recommended dose is 1 mg of varenicline twice a day after administration in smaller doses for 1 week as follows:
Days 1-3 0.5 mg once a day
Days 4-7 0.5 mg twice a day
Day 8 until the end of treatment 1 mg twice a day
The patient must determine the date of smoking cessation. Champix should usually be started 1-2 weeks before this date. Treatment with Champix should be continued for 12 weeks.
For patients who have successfully stopped smoking at the end of the 12th week, an additional 12-week course of treatment with Champix 1 mg twice daily may be considered to relieve withdrawal symptoms.
A gradual approach to smoking cessation with the use of the drug Champix is ​​recommended for patients who are unable or unwilling to quit smoking abruptly. Patients should reduce their smoking frequency during the first 12 weeks of treatment and quit smoking by the end of this treatment period. Patients should continue to take Champix for another 12 weeks, for a total of 24 weeks of treatment.

Retrying smoking with Champix may be successful for patients who seek to quit smoking themselves but have not been able to do so during previous Champix therapy or have returned to smoking after treatment.
Patients who cannot tolerate the side effects caused by the use of the drug Champix can reduce the dose to 0.5 mg twice a day temporarily or permanently.
Treatment for smoking cessation drugs will be more successful in patients who seek to quit smoking themselves and who receive additional counseling and support.
With the use of drugs to get rid of tobacco dependence, the risk of returning to smoking increases immediately after the end of therapy. Patients at high risk of recurrence should consider phasing out the dose at the end of therapy.
Patients with renal insufficiency. No dose adjustment is required for patients with renal insufficiency ranging from mild (creatinine clearance> 50 ml / min and ≤ 80 ml / min) to moderate (creatinine clearance ≥ 30 ml / min and ≤ 50 ml / min).
In patients with moderate renal insufficiency who cannot tolerate the side effects of the drug, the dose of the drug can be reduced to 1 mg once a day.
For patients with severe renal insufficiency (creatinine clearance <30 ml / min), the recommended dose of Champix is ​​1 mg once daily. The first 3 days should take 0.5 mg 1 time per day, and then increase the dose to 1 mg 1 time per day.
Clinical experience with the treatment of Champix in patients with end-stage renal disease is limited, therefore the use of the drug in this category of patients is not recommended.
Patients with hepatic insufficiency. Patients with hepatic insufficiency do not need to change the dose.
Elderly patients. Elderly patients do not need to change the dose of the drug. Because it is likely that renal function is impaired in patients of this age group, the renal status of an elderly patient should be considered when prescribing the drug.
Children
Safety and effectiveness of the drug in children have not been established. Existing information is given in the section “Pharmacological properties. Pharmacokinetics “, but there are no recommendations on the dosage regimen.
Overdose
No overdose has been reported in clinical trials.
In case of overdose it is necessary to carry out usual symptomatic therapy.
Varenicline has been shown to be excreted by dialysis in patients with end-stage renal disease (see Pharmacodynamic Properties), but there is no experience with dialysis after overdose.

Side effects:

  • Infections and invasions: nasopharyngitis, bronchitis, sinusitis, fungal infections, viral infections.
  • Metabolism and nutritional disorders: weight gain, decreased appetite, increased appetite, hyperglycemia.
  • From the psyche: abnormal dreams, insomnia.
  • From the nervous system: headache, drowsiness, dizziness, dysgeusia.
  • Respiratory, thoracic and mediastinal disorders: cough, inflammation of the upper respiratory tract, accumulation of secretions in the respiratory tract, dysphonia, allergic rhinitis, throat irritation, sinus congestion, cough syndrome of the upper respiratory tract, gonorrhea, pain, rhinorrhea, pain.
  • From the gastrointestinal tract: nausea, gastroesophageal reflux disease, vomiting, constipation, diarrhea, bloating, abdominal pain, toothache, dyspepsia, flatulence, dry mouth, fresh blood in the stool, gastritis, changes in bowel rhythm, belching , aphthous stomatitis, gum pain.
  • From the skin and subcutaneous tissue: rash, itching, erythema, acne, sweating, night sweats, severe skin reactions, including Stevens-Johnson syndrome, erythema multiforme, angioneurotic edema.
  • From the musculoskeletal system and connective tissue: arthralgia, myalgia, back pain, muscle spasms, musculoskeletal pain in the chest, joint rigidity, costal chondritis.
  • From the kidneys and urinary system: pollakiuria, nocturia, glucosuria, polyuria.
  • From the reproductive system and mammary glands: menorrhagia, vaginal discharge, sexual dysfunction.
  • General disorders and administration site conditions: chest pain, fatigue, chest discomfort, flu-like illness, pyrexia, asthenia, weakness, feeling cold, cyst.

Expiration date
3 years.
Storage conditions
Store at a temperature not exceeding 30 ° C out of reach of children